> top > docs > PMC:7408073 > spans > 95877-112683 > annotations

PMC:7408073 / 95877-112683 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T1 4247-4262 Body_part denotes digestive tract http://purl.org/sig/ont/fma/fma317863
T2 4291-4296 Body_part denotes bowel http://purl.org/sig/ont/fma/fma7199
T3 4752-4757 Body_part denotes blood http://purl.org/sig/ont/fma/fma9670
T4 4808-4816 Body_part denotes capsules http://purl.org/sig/ont/fma/fma85272
T5 4952-4960 Body_part denotes capsules http://purl.org/sig/ont/fma/fma85272
T6 5185-5189 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T7 5346-5350 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T8 5418-5435 Body_part denotes respiratory tract http://purl.org/sig/ont/fma/fma265130
T9 6441-6445 Body_part denotes face http://purl.org/sig/ont/fma/fma24728
T10 6479-6483 Body_part denotes hand http://purl.org/sig/ont/fma/fma9712
T11 6863-6868 Body_part denotes heart http://purl.org/sig/ont/fma/fma7088
T12 6869-6873 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T13 6874-6879 Body_part denotes liver http://purl.org/sig/ont/fma/fma7197
T14 6880-6889 Body_part denotes intestine http://purl.org/sig/ont/fma/fma7199
T15 6890-6896 Body_part denotes kidney http://purl.org/sig/ont/fma/fma7203
T16 6897-6910 Body_part denotes immune system http://purl.org/sig/ont/fma/fma9825
T17 6911-6916 Body_part denotes blood http://purl.org/sig/ont/fma/fma9670
T18 7058-7063 Body_part denotes blood http://purl.org/sig/ont/fma/fma9670
T19 7154-7160 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T20 7305-7309 Body_part denotes face http://purl.org/sig/ont/fma/fma24728
T21 7642-7646 Body_part denotes sole http://purl.org/sig/ont/fma/fma25000
T22 7877-7881 Body_part denotes face http://purl.org/sig/ont/fma/fma24728
T23 9055-9067 Body_part denotes cell surface http://purl.org/sig/ont/fma/fma67653
T24 9055-9059 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T25 9804-9812 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T26 9900-9915 Body_part denotes coronary artery http://purl.org/sig/ont/fma/fma49893
T27 10137-10142 Body_part denotes heart http://purl.org/sig/ont/fma/fma7088
T28 10983-11005 Body_part denotes gastrointestinal tract http://purl.org/sig/ont/fma/fma71132
T29 11200-11206 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T30 11233-11243 Body_part denotes intestinal http://purl.org/sig/ont/fma/fma7199
T31 11957-11962 Body_part denotes blood http://purl.org/sig/ont/fma/fma9670
T32 12330-12334 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T33 12335-12341 Body_part denotes tissue http://purl.org/sig/ont/fma/fma9637
T34 13460-13464 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T35 14258-14264 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T36 15046-15051 Body_part denotes blood http://purl.org/sig/ont/fma/fma9670
T37 15062-15072 Body_part denotes eosinophil http://purl.org/sig/ont/fma/fma62861
T38 15230-15246 Body_part denotes epithelial cells http://purl.org/sig/ont/fma/fma66768
T39 15241-15246 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T510 474-478 Body_part denotes axis http://purl.org/sig/ont/fma/fma12520
T511 1368-1372 Body_part denotes face http://purl.org/sig/ont/fma/fma24728
T512 2569-2574 Body_part denotes lungs http://purl.org/sig/ont/fma/fma68877
T513 2718-2726 Body_part denotes proteins http://purl.org/sig/ont/fma/fma67257
T514 3653-3660 Body_part denotes insulin http://purl.org/sig/ont/fma/fma83365

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T193 1368-1372 Body_part denotes face http://purl.obolibrary.org/obo/UBERON_0001456
T194 1993-1996 Body_part denotes RAS http://purl.obolibrary.org/obo/UBERON_0018229
T195 4247-4262 Body_part denotes digestive tract http://purl.obolibrary.org/obo/UBERON_0001555
T196 4752-4757 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178
T197 5185-5189 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048
T198 5346-5350 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048
T199 5418-5435 Body_part denotes respiratory tract http://purl.obolibrary.org/obo/UBERON_0000065
T200 5948-5951 Body_part denotes RAS http://purl.obolibrary.org/obo/UBERON_0018229
T201 6441-6445 Body_part denotes face http://purl.obolibrary.org/obo/UBERON_0001456
T202 6479-6483 Body_part denotes hand http://purl.obolibrary.org/obo/UBERON_0002398
T203 6863-6868 Body_part denotes heart http://purl.obolibrary.org/obo/UBERON_0000948
T204 6869-6873 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048
T205 6874-6879 Body_part denotes liver http://purl.obolibrary.org/obo/UBERON_0002107
T206 6880-6889 Body_part denotes intestine http://purl.obolibrary.org/obo/UBERON_0000160
T207 6890-6896 Body_part denotes kidney http://purl.obolibrary.org/obo/UBERON_0002113
T208 6897-6910 Body_part denotes immune system http://purl.obolibrary.org/obo/UBERON_0002405
T209 6911-6916 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178
T210 7058-7063 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178
T211 7305-7309 Body_part denotes face http://purl.obolibrary.org/obo/UBERON_0001456
T212 7531-7534 Body_part denotes RAS http://purl.obolibrary.org/obo/UBERON_0018229
T213 7877-7881 Body_part denotes face http://purl.obolibrary.org/obo/UBERON_0001456
T214 8049-8052 Body_part denotes RAS http://purl.obolibrary.org/obo/UBERON_0018229
T215 8644-8647 Body_part denotes RAS http://purl.obolibrary.org/obo/UBERON_0018229
T216 9240-9243 Body_part denotes RAS http://purl.obolibrary.org/obo/UBERON_0018229
T217 9599-9602 Body_part denotes RAS http://purl.obolibrary.org/obo/UBERON_0018229
T218 9900-9915 Body_part denotes coronary artery http://purl.obolibrary.org/obo/UBERON_0001621
T219 9909-9915 Body_part denotes artery http://purl.obolibrary.org/obo/UBERON_0001637
T220 9978-9981 Body_part denotes RAS http://purl.obolibrary.org/obo/UBERON_0018229
T221 10137-10142 Body_part denotes heart http://purl.obolibrary.org/obo/UBERON_0000948
T222 11957-11962 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178
T223 12330-12334 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048
T224 12335-12341 Body_part denotes tissue http://purl.obolibrary.org/obo/UBERON_0000479
T225 13460-13464 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048
T226 15046-15051 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178
T227 15113-15116 Body_part denotes RAS http://purl.obolibrary.org/obo/UBERON_0018229
T228 15831-15834 Body_part denotes RAS http://purl.obolibrary.org/obo/UBERON_0018229
T229 16308-16311 Body_part denotes RAS http://purl.obolibrary.org/obo/UBERON_0018229

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
3329 48-56 Disease denotes COVID-19 MESH:C000657245
3347 112-116 Gene denotes ACE2 Gene:59272
3348 230-234 Gene denotes ACE2 Gene:59272
3349 383-387 Gene denotes ACE2 Gene:59272
3350 454-458 Gene denotes ACE2 Gene:59272
3351 488-492 Gene denotes ACE2 Gene:59272
3352 513-516 Gene denotes ACE Gene:59272
3353 517-521 Gene denotes ACE2 Gene:59272
3354 670-674 Gene denotes ACE2 Gene:59272
3355 701-705 Gene denotes MasR Gene:116511
3356 725-730 Gene denotes renin Gene:5972
3357 469-473 Gene denotes MasR Gene:116511
3358 158-166 Species denotes patients Tax:9606
3359 340-350 Species denotes SARS-CoV-2 Tax:2697049
3360 459-467 Gene denotes Ang (1–7 Gene:27329
3361 749-754 Chemical denotes metal MESH:D008670
3362 149-157 Disease denotes COVID-19 MESH:C000657245
3363 596-603 Disease denotes hypoxia MESH:D000860
3387 843-847 Gene denotes ACE2 Gene:59272
3388 977-981 Gene denotes ACE2 Gene:70008
3389 1074-1078 Gene denotes ACE2 Gene:70008
3390 1271-1275 Gene denotes ACE2 Gene:59272
3391 1490-1494 Gene denotes ACE2 Gene:59272
3392 1454-1457 Gene denotes MLN Gene:4295
3393 1298-1301 Gene denotes MLN Gene:4295
3394 904-908 Gene denotes MasR Gene:116511
3395 837-842 Species denotes human Tax:9606
3396 898-903 Species denotes human Tax:9606
3397 1026-1031 Species denotes mouse Tax:10090
3398 1032-1035 Species denotes rat Tax:10116
3399 1058-1063 Species denotes human Tax:9606
3400 1068-1073 Species denotes mouse Tax:10090
3401 1094-1099 Species denotes mouse Tax:10090
3402 1129-1134 Species denotes mouse Tax:10090
3403 1135-1138 Species denotes rat Tax:10116
3404 1189-1194 Species denotes human Tax:9606
3405 1195-1207 Species denotes participants Tax:9606
3406 1265-1270 Species denotes human Tax:9606
3407 1542-1548 Species denotes humans Tax:9606
3408 1110-1117 Disease denotes colitis MESH:D003092
3409 1238-1246 Disease denotes toxicity MESH:D064420
3416 1720-1724 Gene denotes ACE2 Gene:59272
3417 1832-1836 Gene denotes ACE2 Gene:59272
3418 1714-1719 Species denotes human Tax:9606
3419 1819-1824 Species denotes human Tax:9606
3420 2022-2030 Species denotes patients Tax:9606
3421 2010-2018 Disease denotes COVID-19 MESH:C000657245
3424 2175-2179 Gene denotes ACE2 Gene:59272
3425 2181-2184 Gene denotes MLN Gene:4295
3437 2462-2466 Gene denotes ACE2 Gene:59272
3438 2608-2612 Gene denotes ACE2 Gene:59272
3439 2698-2702 Gene denotes ACE2 Gene:59272
3440 2780-2784 Gene denotes ACE2 Gene:59272
3441 2805-2809 Gene denotes ACE2 Gene:59272
3442 2712-2717 Gene denotes spike Gene:43740568
3443 2587-2595 Species denotes patients Tax:9606
3444 2602-2607 Species denotes human Tax:9606
3445 2821-2831 Species denotes SARS-CoV-2 Tax:2697049
3446 2535-2546 Disease denotes hypercapnia MESH:D006935
3447 2578-2586 Disease denotes COVID-19 MESH:C000657245
3451 2982-2986 Gene denotes ACE2 Gene:59272
3452 3086-3090 Gene denotes ACE2 Gene:59272
3453 3190-3196 Species denotes humans Tax:9606
3457 3444-3448 Gene denotes ACE2 Gene:59272
3458 3653-3660 Gene denotes insulin Gene:3630
3459 3554-3559 Chemical denotes water MESH:D014867
3466 3814-3818 Gene denotes ACE2 Gene:59272
3467 3777-3790 Chemical denotes disodium salt
3468 3978-4008 Chemical denotes 2-hydroxypropyl-β-cyclodextrin MESH:D000073738
3469 4010-4015 Chemical denotes HPBDC
3470 4021-4024 Chemical denotes H2O
3471 4053-4059 Chemical denotes GL1001 MESH:C486469
3477 4372-4376 Gene denotes ACE2 Gene:59272
3478 4148-4151 Gene denotes MLN Gene:4295
3479 4126-4132 Species denotes humans Tax:9606
3480 4278-4304 Disease denotes Inflammatory bowel disease MESH:D015212
3481 4306-4327 Disease denotes gastritis and colitis MESH:D005756
3490 5326-5330 Gene denotes ACE2 Gene:59272
3491 5551-5554 Gene denotes MLN Gene:4295
3492 5098-5101 Gene denotes MLN Gene:69563
3493 5199-5203 Species denotes mice Tax:10090
3494 5207-5218 Species denotes Pseudomonas Tax:287
3495 5185-5198 Disease denotes lung-infected MESH:D012141
3496 5346-5363 Disease denotes lung inflammation MESH:D011014
3497 5538-5546 Disease denotes toxicity MESH:D064420
3499 3342-3348 Species denotes humans Tax:9606
3504 2337-2341 Gene denotes ACE2 Gene:59272
3505 2318-2321 Gene denotes MLN Gene:4295
3506 2244-2252 Species denotes patients Tax:9606
3507 2235-2243 Disease denotes COVID-19 MESH:C000657245
3528 6032-6035 Gene denotes ACE Gene:59272
3529 6036-6040 Gene denotes ACE2 Gene:59272
3530 6060-6063 Gene denotes ACE Gene:59272
3531 6122-6126 Gene denotes ACE2 Gene:59272
3532 6806-6810 Gene denotes ACE2 Gene:59272
3533 6971-6975 Gene denotes ACE2 Gene:59272
3534 7216-7220 Gene denotes ACE2 Gene:59272
3535 6614-6617 Gene denotes MLN Gene:4295
3536 6302-6305 Gene denotes MLN Gene:4295
3537 5631-5634 Gene denotes MLN Gene:4295
3538 5815-5823 Species denotes patients Tax:9606
3539 6240-6248 Species denotes patients Tax:9606
3540 6777-6785 Species denotes patients Tax:9606
3541 7036-7044 Species denotes patients Tax:9606
3542 7148-7153 Species denotes human Tax:9606
3543 7257-7265 Species denotes patients Tax:9606
3544 7424-7431 Species denotes patient Tax:9606
3545 5911-5929 Disease denotes hypoxic conditions MESH:D000071069
3546 6231-6239 Disease denotes COVID-19 MESH:C000657245
3547 7027-7035 Disease denotes COVID-19 MESH:C000657245
3549 7463-7468 Gene denotes Renin Gene:5972
3574 7607-7612 Gene denotes renin Gene:5972
3575 8159-8162 Gene denotes ACE Gene:59272
3576 8167-8171 Gene denotes ACE2 Gene:59272
3577 8279-8283 Gene denotes AT1R Gene:24180
3578 8410-8415 Gene denotes renin Gene:24715
3579 8555-8559 Gene denotes AT2R Gene:24182
3580 8564-8568 Gene denotes ACE2 Gene:59272
3581 8288-8292 Gene denotes MasR Gene:116511
3582 8377-8385 Gene denotes Ang (1–7 Gene:305843
3583 7571-7576 Gene denotes renin Gene:5972
3584 7959-7967 Species denotes patients Tax:9606
3585 8240-8244 Species denotes rats Tax:10116
3586 8366-8372 Gene denotes Ang II Gene:24179
3587 7811-7820 Chemical denotes Aliskiren MESH:C446481
3588 8217-8226 Chemical denotes Aliskiren MESH:C446481
3589 8698-8707 Chemical denotes CaNa2EDTA
3590 8711-8724 Chemical denotes nicotianamine MESH:C082893
3591 7791-7803 Disease denotes hypertension MESH:D006973
3592 7882-7890 Disease denotes COVID-19 MESH:C000657245
3593 7926-7946 Disease denotes SARS-CoV-2 infection MESH:C000657245
3594 7992-8000 Disease denotes COVID-19 MESH:C000657245
3595 8001-8008 Disease denotes hypoxia MESH:D000860
3596 8172-8185 Disease denotes hyperactivity MESH:D006948
3597 8475-8495 Disease denotes SARS-CoV-2 infection MESH:C000657245
3599 8796-8805 Chemical denotes CaNa2EDTA
3623 8952-8956 Gene denotes ACE2 Gene:59272
3624 8961-8964 Gene denotes ACE Gene:59272
3625 8992-8996 Gene denotes ACE2 Gene:59272
3626 9002-9005 Gene denotes ACE Gene:59272
3627 10374-10377 Gene denotes ACE Gene:59272
3628 10382-10386 Gene denotes ACE2 Gene:59272
3629 9285-9290 Gene denotes renin Gene:5972
3630 9775-9783 Gene denotes Ang-(1–7 Gene:284
3631 9841-9849 Species denotes patients Tax:9606
3632 10355-10363 Species denotes patients Tax:9606
3633 10115-10124 Chemical denotes CaNa2EDTA
3634 8902-8915 Disease denotes hyperactivity MESH:D006948
3635 9151-9171 Disease denotes SARS-CoV-2 infection MESH:C000657245
3636 9214-9221 Disease denotes hypoxia MESH:D000860
3637 9450-9458 Disease denotes COVID-19 MESH:C000657245
3638 9525-9545 Disease denotes SARS-CoV-2 infection MESH:C000657245
3639 9668-9672 Disease denotes ARDS MESH:D012128
3640 9722-9729 Disease denotes hypoxia MESH:D000860
3641 9734-9749 Disease denotes cardiac failure MESH:D006333
3642 9864-9868 Disease denotes ARDS MESH:D012128
3643 9900-9923 Disease denotes coronary artery disease MESH:D003324
3644 10034-10046 Disease denotes dysfunctions MESH:D009461
3645 10128-10150 Disease denotes coronary heart disease MESH:D003324
3669 11353-11356 Species denotes men Tax:9606
3670 11934-11942 Species denotes patients Tax:9606
3671 13188-13195 Species denotes patient Tax:9606
3672 10809-10816 Chemical denotes calcium MESH:D002118
3673 10825-10834 Chemical denotes CaNa2EDTA
3674 10947-10956 Chemical denotes CaNa2EDTA
3675 11162-11171 Chemical denotes CaNa2EDTA
3676 11427-11436 Chemical denotes CaNa2EDTA
3677 11469-11478 Chemical denotes CaNa2EDTA
3678 11690-11699 Chemical denotes CaNa2EDTA
3679 11794-11803 Chemical denotes CaNa2EDTA
3680 12016-12025 Chemical denotes CaNa2EDTA
3681 12220-12229 Chemical denotes CaNa2EDTA
3682 12302-12307 Chemical denotes metal MESH:D008670
3683 12422-12426 Chemical denotes EDTA MESH:D004492
3684 12712-12721 Chemical denotes CaNa2EDTA
3685 12992-13001 Chemical denotes CaNa2EDTA
3686 10893-10902 Disease denotes poisoning MESH:D011041
3687 11825-11834 Disease denotes poisoning MESH:D011041
3688 12193-12200 Disease denotes painful MESH:D010146
3689 13034-13042 Disease denotes COVID-19 MESH:C000657245
3690 13149-13157 Disease denotes COVID-19 MESH:C000657245
3691 13267-13275 Disease denotes toxicity MESH:D064420
3701 13534-13538 Gene denotes AT1R Gene:185
3702 13547-13551 Gene denotes AT2R Gene:24182
3703 13542-13546 Gene denotes MasR Gene:116511
3704 13679-13687 Species denotes patients Tax:9606
3705 13409-13420 Disease denotes dysfunction MESH:D009461
3706 13440-13459 Disease denotes cardiac dysfunction MESH:D006331
3707 13477-13487 Disease denotes thrombosis MESH:D013927
3708 13642-13653 Disease denotes dysfunction MESH:D009461
3709 13689-13697 Disease denotes COVID-19 MESH:C000657245
3733 14314-14321 Gene denotes albumin Gene:213
3734 14323-14328 Gene denotes IL-10 Gene:3586
3735 14330-14338 Gene denotes Ang (1–9 Gene:284
3736 14352-14360 Gene denotes Ang (1–5 Gene:284
3737 14369-14379 Gene denotes bradykinin Gene:3827
3738 14438-14441 Gene denotes ACE Gene:59272
3739 14449-14453 Gene denotes ACE2 Gene:59272
3740 14533-14536 Gene denotes ACE Gene:59272
3741 14541-14545 Gene denotes ACE2 Gene:59272
3742 15280-15284 Gene denotes ACE2 Gene:59272
3743 14341-14349 Gene denotes Ang (1–7 Gene:284
3744 14292-14299 Gene denotes albumin Gene:213
3745 14626-14634 Species denotes patients Tax:9606
3746 14777-14785 Species denotes patients Tax:9606
3747 14985-14992 Species denotes patient Tax:9606
3748 14272-14276 Chemical denotes Zn2+
3749 14034-14046 Disease denotes dysfunctions MESH:D009461
3750 14183-14191 Disease denotes COVID-19 MESH:C000657245
3751 14617-14625 Disease denotes COVID-19 MESH:C000657245
3752 14651-14679 Disease denotes eosinopaenia and hypotension MESH:D007022
3753 15147-15159 Disease denotes inflammation MESH:D007249
3754 15360-15380 Disease denotes SARS-CoV-2 infection MESH:C000657245
3755 15453-15461 Disease denotes COVID-19 MESH:C000657245
3762 15926-15930 Gene denotes ACE2 Gene:59272
3763 15995-15999 Gene denotes ACE2 Gene:59272
3764 16127-16135 Species denotes patients Tax:9606
3765 15684-15692 Disease denotes COVID-19 MESH:C000657245
3766 15765-15773 Disease denotes COVID-19 MESH:C000657245
3767 16422-16429 Disease denotes failure MESH:D006333

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T542 48-56 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T543 149-157 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T544 340-348 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T545 340-344 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T546 1110-1117 Disease denotes colitis http://purl.obolibrary.org/obo/MONDO_0005292
T547 2010-2018 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T548 2235-2243 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T549 2578-2586 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T550 2821-2829 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T551 2821-2825 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T552 3415-3418 Disease denotes DLM http://purl.obolibrary.org/obo/MONDO_0016745
T553 3596-3603 Disease denotes sterile http://purl.obolibrary.org/obo/MONDO_0005047
T554 3768-3771 Disease denotes DLM http://purl.obolibrary.org/obo/MONDO_0016745
T555 4263-4276 Disease denotes inflammations http://purl.obolibrary.org/obo/MONDO_0021166
T556 4278-4304 Disease denotes Inflammatory bowel disease http://purl.obolibrary.org/obo/MONDO_0005265
T557 4306-4315 Disease denotes gastritis http://purl.obolibrary.org/obo/MONDO_0004966
T558 4320-4327 Disease denotes colitis http://purl.obolibrary.org/obo/MONDO_0005292
T559 5351-5363 Disease denotes inflammation http://purl.obolibrary.org/obo/MONDO_0021166
T560 5442-5446 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T561 6231-6239 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T562 7027-7035 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T563 7791-7803 Disease denotes hypertension http://purl.obolibrary.org/obo/MONDO_0005044
T564 7882-7890 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T565 7926-7934 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T566 7926-7930 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T567 7937-7946 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T568 7992-8000 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T569 8475-8483 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T570 8475-8479 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T571 8486-8495 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T572 9151-9159 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T573 9151-9155 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T574 9162-9171 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T575 9450-9458 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T576 9525-9533 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T577 9525-9529 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T578 9536-9545 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T579 9668-9672 Disease denotes ARDS http://purl.obolibrary.org/obo/MONDO_0006502
T580 9674-9677 Disease denotes PAH http://purl.obolibrary.org/obo/MONDO_0015924
T581 9734-9749 Disease denotes cardiac failure http://purl.obolibrary.org/obo/MONDO_0005252
T582 9864-9868 Disease denotes ARDS http://purl.obolibrary.org/obo/MONDO_0006502
T583 9873-9876 Disease denotes PAH http://purl.obolibrary.org/obo/MONDO_0015924
T584 9900-9923 Disease denotes coronary artery disease http://purl.obolibrary.org/obo/MONDO_0005010
T585 9909-9923 Disease denotes artery disease http://purl.obolibrary.org/obo/MONDO_0000473
T586 10128-10150 Disease denotes coronary heart disease http://purl.obolibrary.org/obo/MONDO_0005010
T587 10137-10150 Disease denotes heart disease http://purl.obolibrary.org/obo/MONDO_0005267
T588 10888-10902 Disease denotes lead poisoning http://purl.obolibrary.org/obo/MONDO_0018019
T589 10893-10902 Disease denotes poisoning http://purl.obolibrary.org/obo/MONDO_0029000
T590 11820-11834 Disease denotes lead poisoning http://purl.obolibrary.org/obo/MONDO_0018019
T591 11825-11834 Disease denotes poisoning http://purl.obolibrary.org/obo/MONDO_0029000
T592 12308-12318 Disease denotes poisonings http://purl.obolibrary.org/obo/MONDO_0029000
T593 13034-13042 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T594 13149-13157 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T595 13477-13487 Disease denotes thrombosis http://purl.obolibrary.org/obo/MONDO_0000831
T596 13689-13697 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T597 14183-14191 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T598 14617-14625 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T599 14668-14679 Disease denotes hypotension http://purl.obolibrary.org/obo/MONDO_0005468
T600 15147-15159 Disease denotes inflammation http://purl.obolibrary.org/obo/MONDO_0021166
T601 15360-15368 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T602 15360-15364 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T603 15371-15380 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T604 15453-15461 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T605 15522-15525 Disease denotes flu http://purl.obolibrary.org/obo/MONDO_0005812
T606 15684-15692 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T607 15765-15773 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T1 4126-4132 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes humans
T2 4182-4188 http://purl.obolibrary.org/obo/UBERON_0000473 denotes tested
T3 4247-4262 http://purl.obolibrary.org/obo/UBERON_0001555 denotes digestive tract
T4 4381-4382 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T5 4400-4407 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T6 4752-4757 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
T7 4752-4757 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood
T8 4934-4940 http://purl.obolibrary.org/obo/CLO_0001658 denotes active
T9 4974-4975 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T10 5185-5189 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T11 5185-5189 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung
T12 5219-5227 http://purl.obolibrary.org/obo/NCBITaxon_2 denotes bacteria
T13 5346-5350 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T14 5346-5350 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung
T15 5827-5828 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T16 5936-5940 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arms
T17 5983-5984 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T18 6137-6145 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T19 6416-6424 http://purl.obolibrary.org/obo/CLO_0001658 denotes actively
T20 6441-6445 http://purl.obolibrary.org/obo/UBERON_0001456 denotes face
T21 6561-6563 http://purl.obolibrary.org/obo/CLO_0050475 denotes my
T22 6795-6796 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T23 6863-6868 http://purl.obolibrary.org/obo/UBERON_0000948 denotes heart
T24 6863-6868 http://purl.obolibrary.org/obo/UBERON_0007100 denotes heart
T25 6863-6868 http://purl.obolibrary.org/obo/UBERON_0015228 denotes heart
T26 6863-6868 http://www.ebi.ac.uk/efo/EFO_0000815 denotes heart
T27 6869-6873 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T28 6869-6873 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung
T29 6874-6879 http://purl.obolibrary.org/obo/UBERON_0002107 denotes liver
T30 6874-6879 http://www.ebi.ac.uk/efo/EFO_0000887 denotes liver
T31 6880-6889 http://purl.obolibrary.org/obo/UBERON_0000160 denotes intestine
T32 6880-6889 http://www.ebi.ac.uk/efo/EFO_0000834 denotes intestine
T33 6890-6896 http://purl.obolibrary.org/obo/UBERON_0002113 denotes kidney
T34 6890-6896 http://www.ebi.ac.uk/efo/EFO_0000927 denotes kidney
T35 6890-6896 http://www.ebi.ac.uk/efo/EFO_0000929 denotes kidney
T36 6897-6910 http://purl.obolibrary.org/obo/UBERON_0002405 denotes immune system
T37 6911-6916 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
T38 6911-6916 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood
T39 7058-7063 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
T40 7058-7063 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood
T41 7089-7097 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T42 7136-7144 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T43 7148-7153 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T44 7154-7160 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T45 7199-7202 http://purl.obolibrary.org/obo/CLO_0001046 denotes 116
T46 7221-7231 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T47 7286-7294 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T48 7305-7309 http://purl.obolibrary.org/obo/UBERON_0001456 denotes face
T49 7353-7354 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T50 7469-7477 http://purl.obolibrary.org/obo/CLO_0001658 denotes Activity
T51 7587-7595 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T52 7877-7881 http://purl.obolibrary.org/obo/UBERON_0001456 denotes face
T53 8037-8041 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arms
T54 8084-8085 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T55 8245-8248 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T56 8331-8332 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T57 8511-8514 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T58 8595-8596 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T59 8632-8636 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arms
T60 9017-9025 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T61 9055-9059 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T62 9228-9232 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arms
T63 9587-9591 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arms
T64 9802-9803 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T65 9909-9915 http://purl.obolibrary.org/obo/UBERON_0001637 denotes artery
T66 9909-9915 http://www.ebi.ac.uk/efo/EFO_0000814 denotes artery
T67 9966-9970 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arms
T68 10057-10058 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T69 10137-10142 http://purl.obolibrary.org/obo/UBERON_0000948 denotes heart
T70 10137-10142 http://purl.obolibrary.org/obo/UBERON_0007100 denotes heart
T71 10137-10142 http://purl.obolibrary.org/obo/UBERON_0015228 denotes heart
T72 10137-10142 http://www.ebi.ac.uk/efo/EFO_0000815 denotes heart
T73 10463-10473 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T74 10714-10715 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T75 10738-10739 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T76 10983-11005 http://purl.obolibrary.org/obo/UBERON_0005409 denotes gastrointestinal tract
T77 11200-11206 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T78 11233-11243 http://purl.obolibrary.org/obo/UBERON_0000160 denotes intestinal
T79 11233-11243 http://www.ebi.ac.uk/efo/EFO_0000834 denotes intestinal
T80 11310-11318 http://purl.obolibrary.org/obo/OBI_0100026 denotes organism
T81 11310-11318 http://purl.obolibrary.org/obo/UBERON_0000468 denotes organism
T82 11405-11406 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T83 11486-11487 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T84 11957-11962 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
T85 11957-11962 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood
T86 11983-11987 http://purl.obolibrary.org/obo/CLO_0003535 denotes g/m2
T87 12118-12119 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T88 12244-12247 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T89 12330-12334 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T90 12330-12334 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung
T91 12876-12879 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T92 12880-12881 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T93 13178-13179 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T94 13460-13464 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T95 13460-13464 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung
T96 13513-13523 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T97 13701-13702 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T98 13884-13885 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T99 13908-13909 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T100 14258-14264 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T101 14464-14472 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T102 14546-14554 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T103 15046-15051 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
T104 15046-15051 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood
T105 15117-15125 http://purl.obolibrary.org/obo/PR_000018263 denotes peptides
T106 15166-15169 http://purl.obolibrary.org/obo/PR_000001343 denotes aim
T107 15230-15240 http://purl.obolibrary.org/obo/CL_0000066 denotes epithelial
T108 15241-15246 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T109 15513-15514 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T110 15527-15528 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T111 15733-15734 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T112 15946-15949 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T113 15979-15987 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T114 16156-16157 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T115 16341-16343 http://purl.obolibrary.org/obo/CLO_0050475 denotes my
T116 16396-16397 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T117 16420-16421 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T1169 200-201 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T1170 286-292 http://purl.obolibrary.org/obo/CLO_0001658 denotes active
T1171 302-304 http://purl.obolibrary.org/obo/CLO_0050050 denotes S1
T1172 837-842 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T1173 861-869 http://purl.obolibrary.org/obo/UBERON_0000158 denotes membrane
T1174 898-903 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T1175 909-915 http://purl.obolibrary.org/obo/SO_0000418 denotes signal
T1176 939-940 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T41156 1026-1031 http://purl.obolibrary.org/obo/CLO_0007836 denotes mouse
T1178 1058-1063 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T1179 1068-1073 http://purl.obolibrary.org/obo/CLO_0007836 denotes mouse
T1180 1079-1087 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T1181 1094-1099 http://purl.obolibrary.org/obo/CLO_0007836 denotes mouse
T1182 1129-1134 http://purl.obolibrary.org/obo/CLO_0007836 denotes mouse
T1183 1189-1194 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T1184 1211-1214 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T1185 1265-1270 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T1186 1307-1310 http://purl.obolibrary.org/obo/CLO_0002096 denotes C16
T1187 1368-1372 http://purl.obolibrary.org/obo/UBERON_0001456 denotes face
T1188 1430-1432 http://purl.obolibrary.org/obo/CLO_0050475 denotes my
T1189 1463-1466 http://purl.obolibrary.org/obo/CLO_0002096 denotes C16
T1190 1515-1518 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T1191 1524-1530 http://purl.obolibrary.org/obo/UBERON_0000473 denotes tested
T1192 1542-1548 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes humans
T1193 1552-1553 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T1194 1676-1683 http://purl.obolibrary.org/obo/CLO_0009985 denotes focused
T1195 1684-1686 http://purl.obolibrary.org/obo/CLO_0050475 denotes my
T1196 1714-1719 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T1197 1819-1824 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T1198 1903-1904 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T1199 2367-2370 http://purl.obolibrary.org/obo/CLO_0002096 denotes C16
T1200 2431-2434 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T1201 2477-2485 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T1202 2569-2574 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lungs
T1203 2602-2607 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T1204 2613-2621 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T1205 2785-2793 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T1206 2848-2850 http://purl.obolibrary.org/obo/CLO_0050050 denotes S1
T1207 2987-2997 http://purl.obolibrary.org/obo/CLO_0001658 denotes activators
T1208 3022-3032 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T1209 3091-3099 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T1210 3162-3163 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T1211 3190-3196 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes humans
T1212 3342-3348 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes humans
T1213 3365-3366 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T1214 3410-3414 http://purl.obolibrary.org/obo/CLO_0002096 denotes C-16
T1215 3449-3459 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T1216 3523-3524 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T1217 3564-3565 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T1218 3615-3616 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T1219 3644-3645 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T1220 3653-3660 http://purl.obolibrary.org/obo/PR_000009054 denotes insulin
T1221 3702-3703 http://purl.obolibrary.org/obo/CLO_0001021 denotes b
T1222 3819-3829 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T1223 3906-3907 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T1224 3933-3934 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T1225 3954-3955 http://purl.obolibrary.org/obo/CLO_0001020 denotes a

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T22916 675-693 Chemical denotes pathway inhibitors http://purl.obolibrary.org/obo/CHEBI_76932
T430 683-693 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T28021 706-717 Chemical denotes antagonists http://purl.obolibrary.org/obo/CHEBI_48706
T432 731-741 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T48464 755-764 Chemical denotes chelators http://purl.obolibrary.org/obo/CHEBI_38161
T39924 784-793 Chemical denotes molecules http://purl.obolibrary.org/obo/CHEBI_25367
T21519 982-1000 Chemical denotes pathway inhibitors http://purl.obolibrary.org/obo/CHEBI_76932
T436 990-1000 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T33321 1287-1296 Chemical denotes molecules http://purl.obolibrary.org/obo/CHEBI_25367
T438 1307-1310 Chemical denotes C16 http://purl.obolibrary.org/obo/CHEBI_15756
T62485 1463-1466 Chemical denotes C16 http://purl.obolibrary.org/obo/CHEBI_15756
T440 1504-1514 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T25711 1700-1710 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T33721 1837-1855 Chemical denotes pathway inhibitors http://purl.obolibrary.org/obo/CHEBI_76932
T20781 1845-1855 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T88121 1993-1996 Chemical denotes RAS http://purl.obolibrary.org/obo/CHEBI_63620
T445 2309-2317 Chemical denotes molecule http://purl.obolibrary.org/obo/CHEBI_25367
T21827 2337-2351 Chemical denotes ACE2 inhibitor http://purl.obolibrary.org/obo/CHEBI_147289
T447 2342-2351 Chemical denotes inhibitor http://purl.obolibrary.org/obo/CHEBI_35222
T82941 2367-2370 Chemical denotes C16 http://purl.obolibrary.org/obo/CHEBI_15756
T449 2718-2726 Chemical denotes proteins http://purl.obolibrary.org/obo/CHEBI_36080
T63759 3554-3559 Chemical denotes water http://purl.obolibrary.org/obo/CHEBI_15377
T53319 3566-3574 Chemical denotes solution http://purl.obolibrary.org/obo/CHEBI_75958
T52282 3617-3625 Chemical denotes solution http://purl.obolibrary.org/obo/CHEBI_75958
T57829 3653-3660 Chemical denotes insulin http://purl.obolibrary.org/obo/CHEBI_145810
T12810 3786-3790 Chemical denotes salt http://purl.obolibrary.org/obo/CHEBI_24866|http://purl.obolibrary.org/obo/CHEBI_26710
T39693 3964-3972 Chemical denotes solution http://purl.obolibrary.org/obo/CHEBI_75958
T31089 3996-4008 Chemical denotes cyclodextrin http://purl.obolibrary.org/obo/CHEBI_23456
T9 4021-4024 Chemical denotes H2O http://purl.obolibrary.org/obo/CHEBI_15377
T3495 4213-4227 Chemical denotes pharmaceutical http://purl.obolibrary.org/obo/CHEBI_52217
T11 4473-4477 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T72202 4941-4945 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T58611 5315-5324 Chemical denotes molecules http://purl.obolibrary.org/obo/CHEBI_25367
T57445 5948-5951 Chemical denotes RAS http://purl.obolibrary.org/obo/CHEBI_63620
T42648 6406-6414 Chemical denotes molecule http://purl.obolibrary.org/obo/CHEBI_25367
T66997 6489-6493 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T55490 7188-7197 Chemical denotes inhibitor http://purl.obolibrary.org/obo/CHEBI_35222
T79112 7531-7534 Chemical denotes RAS http://purl.obolibrary.org/obo/CHEBI_63620
T25987 7613-7623 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T36125 7625-7634 Chemical denotes aliskiren http://purl.obolibrary.org/obo/CHEBI_601027
T21 7673-7678 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888
T68125 7868-7873 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888
T76956 8049-8052 Chemical denotes RAS http://purl.obolibrary.org/obo/CHEBI_63620
T7372 8065-8074 Chemical denotes aliskiren http://purl.obolibrary.org/obo/CHEBI_601027
T80351 8145-8149 Chemical denotes fuel http://purl.obolibrary.org/obo/CHEBI_33292
T53522 8370-8372 Chemical denotes II http://purl.obolibrary.org/obo/CHEBI_74067
T46892 8387-8394 Chemical denotes ligands http://purl.obolibrary.org/obo/CHEBI_52214
T73943 8644-8647 Chemical denotes RAS http://purl.obolibrary.org/obo/CHEBI_63620
T15324 8666-8672 Chemical denotes cation http://purl.obolibrary.org/obo/CHEBI_36916
T26128 8673-8689 Chemical denotes chelating agents http://purl.obolibrary.org/obo/CHEBI_38161
T93640 8711-8724 Chemical denotes nicotianamine http://purl.obolibrary.org/obo/CHEBI_25520|http://purl.obolibrary.org/obo/CHEBI_58249
T78307 8828-8844 Chemical denotes chelating agents http://purl.obolibrary.org/obo/CHEBI_38161
T50244 8858-8862 Chemical denotes zinc http://purl.obolibrary.org/obo/CHEBI_27363|http://purl.obolibrary.org/obo/CHEBI_30185
T86055 9104-9120 Chemical denotes chelating agents http://purl.obolibrary.org/obo/CHEBI_38161
T24696 9240-9243 Chemical denotes RAS http://purl.obolibrary.org/obo/CHEBI_63620
T59302 9291-9301 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T40754 9308-9324 Chemical denotes chelating agents http://purl.obolibrary.org/obo/CHEBI_38161
T43600 9372-9377 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888
T37560 9486-9491 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888
T45827 9599-9602 Chemical denotes RAS http://purl.obolibrary.org/obo/CHEBI_63620
T9258 9674-9677 Chemical denotes PAH http://purl.obolibrary.org/obo/CHEBI_104011|http://purl.obolibrary.org/obo/CHEBI_31204|http://purl.obolibrary.org/obo/CHEBI_33848|http://purl.obolibrary.org/obo/CHEBI_53305
T27101 9768-9770 Chemical denotes II http://purl.obolibrary.org/obo/CHEBI_74067
T63845 9873-9876 Chemical denotes PAH http://purl.obolibrary.org/obo/CHEBI_104011|http://purl.obolibrary.org/obo/CHEBI_31204|http://purl.obolibrary.org/obo/CHEBI_33848|http://purl.obolibrary.org/obo/CHEBI_53305
T5467 9978-9981 Chemical denotes RAS http://purl.obolibrary.org/obo/CHEBI_63620
T76100 10750-10758 Chemical denotes medicine http://purl.obolibrary.org/obo/CHEBI_23888
T57881 10809-10816 Chemical denotes calcium http://purl.obolibrary.org/obo/CHEBI_22984|http://purl.obolibrary.org/obo/CHEBI_29320
T83360 10875-10883 Chemical denotes antidote http://purl.obolibrary.org/obo/CHEBI_50247
T37122 10926-10930 Chemical denotes zinc http://purl.obolibrary.org/obo/CHEBI_27363|http://purl.obolibrary.org/obo/CHEBI_30185
T27252 10931-10939 Chemical denotes chelator http://purl.obolibrary.org/obo/CHEBI_38161
T65049 11207-11211 Chemical denotes zinc http://purl.obolibrary.org/obo/CHEBI_27363|http://purl.obolibrary.org/obo/CHEBI_30185
T28613 11244-11248 Chemical denotes zinc http://purl.obolibrary.org/obo/CHEBI_27363|http://purl.obolibrary.org/obo/CHEBI_30185
T82046 11291-11295 Chemical denotes zinc http://purl.obolibrary.org/obo/CHEBI_27363|http://purl.obolibrary.org/obo/CHEBI_30185
T31373 11565-11569 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T61878 12422-12426 Chemical denotes EDTA http://purl.obolibrary.org/obo/CHEBI_42191|http://purl.obolibrary.org/obo/CHEBI_64755
T17876 12561-12577 Chemical denotes chelating agents http://purl.obolibrary.org/obo/CHEBI_38161
T48035 12867-12875 Chemical denotes chelator http://purl.obolibrary.org/obo/CHEBI_38161
T62900 14272-14275 Chemical denotes Zn2 http://purl.obolibrary.org/obo/CHEBI_37256
T20847 14287-14291 Chemical denotes zinc http://purl.obolibrary.org/obo/CHEBI_27363|http://purl.obolibrary.org/obo/CHEBI_30185
T4937 14323-14325 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T2350 14369-14379 Chemical denotes bradykinin http://purl.obolibrary.org/obo/CHEBI_3165
T24872 15113-15116 Chemical denotes RAS http://purl.obolibrary.org/obo/CHEBI_63620
T53946 15117-15125 Chemical denotes peptides http://purl.obolibrary.org/obo/CHEBI_16670
T12617 15831-15834 Chemical denotes RAS http://purl.obolibrary.org/obo/CHEBI_63620
T93364 15835-15845 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T25023 15899-15903 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T91571 15926-15940 Chemical denotes ACE2 inhibitor http://purl.obolibrary.org/obo/CHEBI_147289
T70701 15931-15940 Chemical denotes inhibitor http://purl.obolibrary.org/obo/CHEBI_35222
T14447 16025-16029 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T92382 16243-16247 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T52971 16308-16311 Chemical denotes RAS http://purl.obolibrary.org/obo/CHEBI_63620

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T1 4263-4276 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammations
T2 5351-5363 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammation
T3 6911-6928 http://purl.obolibrary.org/obo/GO_0007596 denotes blood/coagulation
T4 6917-6928 http://purl.obolibrary.org/obo/GO_0050817 denotes coagulation
T5 8917-8926 http://purl.obolibrary.org/obo/GO_0009058 denotes synthesis
T6 11291-11302 http://purl.obolibrary.org/obo/GO_0071578 denotes zinc uptake
T7 11296-11302 http://purl.obolibrary.org/obo/GO_0098739 denotes uptake
T8 11296-11302 http://purl.obolibrary.org/obo/GO_0098657 denotes uptake
T9 11501-11510 http://purl.obolibrary.org/obo/GO_0007588 denotes excretion
T10 12840-12861 http://purl.obolibrary.org/obo/GO_0003094 denotes glomerular filtration
T11 15147-15159 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammation
T155 909-928 http://purl.obolibrary.org/obo/GO_0007165 denotes signal transduction
T156 916-928 http://purl.obolibrary.org/obo/GO_0009293 denotes transduction

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T463 0-2 Sentence denotes 8.
T464 3-56 Sentence denotes Hypothesizing Pharmacological Treatments for COVID-19
T465 57-167 Sentence denotes Based on the above described hypothesis, inhibition of ACE2 pathway might be beneficial for COVID-19 patients.
T466 168-428 Sentence denotes Indeed, the clinical picture as a whole is consistent with an ACE2 gain of function (possibly due to both circulating active forms of S1-sACE2 complexes and local forms of SARS-CoV-2-sACE2 complexes) rather than an ACE2 loss of function, as initially supposed.
T467 429-623 Sentence denotes Therefore, inhibition of ACE2/Ang (1–7)/MasR axis or other ACE2 pathways to restore ACE/ACE2 balance might be needed, at least in the first phases of the disease when hypoxia is not yet induced.
T468 624-765 Sentence denotes Different strategies could be pursued through ACE2 pathway inhibitors and/or MasR antagonists and/or renin inhibitors and/or metal chelators.
T469 766-971 Sentence denotes Several different molecules have been designed to specifically inhibit human ACE2 enzyme (both membrane bound and soluble forms) or human MasR signal transduction, but only a few have been studied in vivo.
T470 972-1118 Sentence denotes Some ACE2 pathway inhibitors have been widely used in mouse/rat models, as control of human and mouse ACE2 activity or in mouse models of colitis.
T471 1119-1411 Sentence denotes Thanks to mouse/rat in vivo experiments and clinical trial results in human participants it has been possible to infer toxicity/efficacy for some human ACE2 inhibitory molecules (MLN-4760/C16/GL1001/ORE1001, Dx600 and A779) that may be exploited to face this exceptionally dramatic situation.
T472 1412-1662 Sentence denotes Unfortunately, to my knowledge, only one (MLN-4760/C16/GL1001/ORE1001) of the ACE2-specific inhibitors has been tested in vivo in humans in a Phase I clinical trial long time ago (http://oreholdings.com/wp-content/uploads/2013/06/09.02.09-S-4-A.pdf).
T473 1663-1777 Sentence denotes Here, I have focused my attention on inhibitors of human ACE2 pathway that were consistently administered in vivo.
T474 1778-2154 Sentence denotes Making use of published reports in which human/rodent ACE2 pathway inhibitors were administered in vivo, I have hypothesized a possible therapeutic pharmacological intervention through an inhibition strategy of the RAS pathways for COVID-19 in patients experiencing both mild and critical, advanced and untreatable stages of the disease (the most problematic cases to manage).
T475 2156-2160 Sentence denotes 8.1.
T476 2161-2189 Sentence denotes Inhibition of ACE2: MLN-4760
T477 2190-2861 Sentence denotes Briefly, one of the best candidates to treat COVID-19 patients, but not to prevent viral entry, is the small synthetic molecule MLN-4760 (specific ACE2 inhibitor, also known as C16, GL1001 or ORE1001, [113]) for the following reasons:(1) It has been shown to bind/inhibit ACE2 enzymatic activity even at low/acidic pH (pH 6.5, [115]) typical of hypercapnia (as it might occur in lungs of COVID-19 patients) when human ACE2 activity is maximal [79]; nevertheless, it retains its inhibitory effects on soluble ACE2 bound to spike proteins [24], indicating that it is able to bind and inhibit ACE2 activity regardless ACE2 binding to SARS-CoV-2 particles or to S1 fragments.
T478 2862-3266 Sentence denotes (2) No significant adverse effects were described upon its chronic administration neither alone nor in combination with ACE2 activators (while inhibiting their activating effects) nor after inducing functional impairment of ACE2 activity in rodent experiments in vivo [52,117,118,122,183,184] nor in a clinical Phase I trial in humans (http://oreholdings.com/wp-content/uploads/2013/06/09.10.09-425.pdf);
T479 3267-3349 Sentence denotes (3) Its administration by different route is well described in rodents and humans.
T480 3350-3700 Sentence denotes In particular:(a) Chronic administration (about 4 weeks) of C-16/DLM-4760 in combination with ACE2 activating treatments was performed by daily intraperitoneal injection at a dose of 25mg/kg in distilled water (as a solution of 42 mg/mL) or 0.9% sterile saline (as a solution of 84 mg/mL using a 0.5-mL insulin syringe) freshly prepared [52,183,184].
T481 3701-4032 Sentence denotes (b) Alternatively, chronic administration (about 8 days) of GL1001/DLM-4760 disodium salt in combination with an ACE2 activating treatment was performed by subcutaneous injection (5mL/kg) containing up to a dose of 300 mg/kg, twice a day, formulated in a vehicle solution [15% 2-hydroxypropyl-β-cyclodextrin (HPBDC)/85% H2O] [122].
T482 4033-4118 Sentence denotes Subchronic doses of GL1001 indicate no adverse effects up to 1,000 mg/kg (see [122]).
T483 4119-4208 Sentence denotes (c) In humans ORE1001/GL1001/MLN-4760 was already proposed and tested in clinical trials.
T484 4209-4377 Sentence denotes Its pharmaceutical indication was for digestive tract inflammations (Inflammatory bowel disease, gastritis and colitis) that are correlated with overexpression of ACE2.
T485 4378-4454 Sentence denotes In a Phase I clinical testing up 14 days dosing, ORE1001 was well tolerated.
T486 4455-4539 Sentence denotes Subjects received drug (dosing up to 2100 mg) with no side adverse effects reported.
T487 4540-4677 Sentence denotes In particular, 47 subjects received single-dose from 2.1 to 2100 mg and 24 subjects received 14 day multiple doses from 50 mg to 1800 mg.
T488 4678-4767 Sentence denotes All doses were well tolerated, with no significant side effects including blood pressure.
T489 4768-4925 Sentence denotes Pharmacokinetics of orally administered capsules was consistent with once-daily dosing. (http://oreholdings.com/wp-content/uploads/2013/06/09.10.09-425.pdf).
T490 4926-5084 Sentence denotes 300 mg (active drug) oral capsules were used in a Phase Ib/IIa clinical trial that was, however, abandoned. (https://clinicaltrials.gov/ct2/show/NCT01039597).
T491 5085-5234 Sentence denotes (d) Finally, MLN-4760 was also administered (2.5 mg/kg per day) by nasal inhalation for 2–3 days in lung-infected mice by Pseudomonas bacteria [185].
T492 5235-5376 Sentence denotes Interestingly, the report underscores the role played by local concentration of molecules (ACE2) in modulating lung inflammation and disease.
T493 5377-5610 Sentence denotes For these reasons, in diseases involving respiratory tract, like SARS, inhalation treatment is preferable, even for the lower concentration (and hopefully lower toxicity) of MLN-4760 needed for this route of treatment administration.
T494 5611-5726 Sentence denotes Different routes of MLN-4760 treatment administration can be pursued depending on the hospital condition/expertise.
T495 5727-5889 Sentence denotes In this exceptionally critical situation, it could be delivered to critical untreatable patients as a controlled “compassionate use”, in particular by inhalation.
T496 5890-6089 Sentence denotes However, when, under hypoxic conditions, both arms of the RAS are upregulated, it might have a limited action and, by shifting the balance of ACE/ACE2 ratio in favour of ACE, might be even dangerous.
T497 6090-6301 Sentence denotes Instead, specific inhibition of ACE2 enzymatic activity might effectively work in preventing the establishment of positive feedback loops in COVID-19 patients who are suffering from mild symptoms of the disease.
T498 6302-6465 Sentence denotes MLN-4760 is sold by different companies, that, in case it works, could be encouraged to manufacture the molecule, actively contributing to face this global threat.
T499 6466-6613 Sentence denotes On the other hand, the drug could be also synthesized in University chemistry labs because, to my knowledge, is no longer under patent restriction.
T500 6614-7045 Sentence denotes MLN-4760, whose clinical development was abandoned after phase I trials (clinical name, ORE1001), is actually an interesting compound that could be useful for all patients in which a specific ACE2 upregulation is proven and associated to different (heart/lung/liver/intestine/kidney/immune system/blood/coagulation, etc.) pathological conditions related to ACE2 pathway downstream events, as it seems to occur in COVID-19 patients.
T501 7046-7442 Sentence denotes Although in blood of normal subjects sACE2 activity is undetectable because its catalytic activity in human plasma is masked by an endogenous inhibitor [116] and chronic ACE2 activation may be deleterious, some patients might need of sACE2 activity to better face an acute pathological condition, therefore a careful monitoring of clinical parameters should be performed during patient treatment.
T502 7444-7448 Sentence denotes 8.2.
T503 7449-7478 Sentence denotes Inhibition of Renin Activity:
T504 7479-7488 Sentence denotes Aliskiren
T505 7489-7596 Sentence denotes An alternative approach is to inhibit the RAS pathway at its origin by inhibiting renin enzymatic activity.
T506 7597-7810 Sentence denotes Regarding renin inhibitors, aliskiren is the sole compound in this class of drugs that was approved by the US Food and Drug Administration in March 2007 and commercialized for the management of hypertension [186].
T507 7811-7947 Sentence denotes Aliskiren may be used alone or in combination with other drugs to face COVID-19, in particular the severe forms of SARS-CoV-2 infection.
T508 7948-8053 Sentence denotes Indeed, in patients with severe symptoms of COVID-19 hypoxia might have upregulated both arms of the RAS.
T509 8054-8216 Sentence denotes Therefore, aliskiren might be a useful “tool” to reduce production of Ang I, the necessary fuel for both ACE and ACE2 hyperactivity and their detrimental effects.
T510 8217-8433 Sentence denotes Aliskiren treatment in rats has been shown to upregulate both AT1R and MasR expression probably as consequence of a compensation mechanism when both Ang II and Ang (1–7) ligands are reduced by renin inhibition [187].
T511 8434-8654 Sentence denotes Of particular interest in the context of SARS-CoV-2 infection, the treatment has been shown to reduce expression of both AT2R and ACE2, thus possibly performing a multiple action in inhibiting both arms of the RAS [187].
T512 8655-8771 Sentence denotes Similarly, cation chelating agents such as CaNa2EDTA or nicotianamine might also work, although at different levels.
T513 8773-8777 Sentence denotes 8.3.
T514 8778-8795 Sentence denotes Chelating Agents:
T515 8796-8805 Sentence denotes CaNa2EDTA
T516 8806-9084 Sentence denotes As already mentioned, chelating agents, by limiting zinc cellular availability, might influence hyperactivity, synthesis and conformation of both ACE2 and ACE, which may impair not only ACE2 (and ACE) enzymatic activity but also its availability on cell surface for viral entry.
T517 9085-9267 Sentence denotes For these reasons, chelating agents might be effective to counter SARS-CoV-2 infection, and in particular when (e.g., induced by hypoxia) both arms of the RAS are likely upregulated.
T518 9268-9459 Sentence denotes Differently from renin inhibitors, more chelating agents are commercially available and both classes of drugs might be administered, alone or in combination with other therapies for COVID-19.
T519 9460-9750 Sentence denotes Of note, these classes of drugs might be beneficial not only for SARS-CoV-2 infection but also for other disease in which both arms of the RAS (and of the inflammatory system) are upregulated, as for example ARDS, PAH and other pathologies associated to chronic hypoxia and cardiac failure.
T520 9751-10047 Sentence denotes Indeed, both Ang-II and Ang-(1–7) upregulation and a cytokine storm are common aspects in patients not only with ARDS and PAH but also with critical coronary artery disease [182], suggesting an upregulation of both arms of the RAS and of the inflammatory system in several different dysfunctions.
T521 10048-10151 Sentence denotes Notably, a number of clinical trials have indicated the utility of CaNa2EDTA in coronary heart disease.
T522 10152-10271 Sentence denotes It was believed that chelation therapy might alter plaque morphology and volume, or improve endothelial function [123].
T523 10272-10319 Sentence denotes However, the evidence was not convincing [123].
T524 10320-10425 Sentence denotes Future clinical trials on selected patients with both ACE and ACE2 upregulation might be more convincing.
T525 10426-10555 Sentence denotes It is clear that similar pathways of activation can lead to different outcomes depending on individual predisposition/background.
T526 10556-10774 Sentence denotes Therefore, future efforts to understand the genetic, morpho-physiological, environmental and lifestyle factors that individually affect the predisposition to a specific disease with a precision medicine must be pursed.
T527 10775-10946 Sentence denotes To avoid disrupting extracellular calcium levels, CaNa2EDTA formulation is typically employed as an antidote for lead poisoning or as an extracellular zinc chelator [123].
T528 10947-11088 Sentence denotes CaNa2EDTA is poorly absorbed in the gastrointestinal tract therefore can be preferentially administered by parenteral route or by inhalation.
T529 11089-11330 Sentence denotes Nevertheless, oral tablets (e.g., 250–500 mg/tablet) or suppositories of CaNa2EDTA might also work in reducing plasma zinc levels by inhibiting intestinal zinc absorption (the only physiological way of zinc uptake by the organism) [188,189].
T530 11331-11463 Sentence denotes In this regard, eight men showing elevated lead concentrations were given a seven-day course of CaNa2EDTA, 4 g/day in divided doses.
T531 11464-11599 Sentence denotes Oral CaNa2EDTA caused a rise in lead excretion within few hours, suggesting that orally administered drug was partially absorbed [188].
T532 11600-11744 Sentence denotes Importantly, the trial in the eight lead workers demonstrated that oral administration of CaNa2EDTA was safe and produced no side-effects [188].
T533 11745-12015 Sentence denotes However, the FDA-approved method for delivery of CaNa2EDTA in treatment of lead poisoning is intravenously or intramuscularly and the recommended dose for asymptomatic adults and pediatric patients with elevated blood lead levels is 1000 g/m2/day (~0,05 g/kg/day) [190].
T534 12016-12142 Sentence denotes CaNa2EDTA was usually administered for 5–10 days followed by an interval of at least 5–10 days before a second administration.
T535 12143-12201 Sentence denotes Unfortunately, intravenous administration is very painful.
T536 12202-12485 Sentence denotes Administration of CaNa2EDTA via nebulizer has also been pursued for inhalation therapy in pulmonary metal poisonings to protect lung tissue and reduce its systemic uptaken [123]; moreover, nebulized solutions containing EDTA have been proven safe, not inducing adverse effects [191].
T537 12486-12711 Sentence denotes For the sake of completeness, the unconventional methods for administering chelating agents such as rectal or inhalatory administration are not FDA approved methods for delivery and they have not been studied in detail [192].
T538 12712-12862 Sentence denotes CaNa2EDTA diffuses mainly in the extracellular fluids, where it is not significantly metabolized, and it is excreted rapidly by glomerular filtration.
T539 12863-12961 Sentence denotes The chelator has a half-life of 1.4 to 3 h in adults and is completely excreted within 24 h [123].
T540 12962-13043 Sentence denotes For all of the above reasons, CaNa2EDTA might be employed in therapy of COVID-19.
T541 13044-13298 Sentence denotes However, before beginning any therapy with medication, particularly in the case of new diseases (such as COVID-19) or new treatments, a careful patient selection for these new treatments is essential to prevent unnecessary toxicity (“first do not harm”).
T542 13300-13304 Sentence denotes 8.4.
T543 13305-13333 Sentence denotes Safety and Efficacy Concerns
T544 13334-13718 Sentence denotes Unfortunately, diseases of different aetiologies may present similar final dysfunction/alterations (e.g., cardiac dysfunction/lung alterations/thrombosis are induced by excessive activation of either AT1R or MasR/AT2R pathways, see Figure 1), while diseases with same aetiologies may present different final dysfunction/alterations depending on patients (COVID-19 is a clear example).
T545 13719-13931 Sentence denotes This confounding aspect of diseases can lead to erroneous interpretations, and only defining the correct and early molecular origin of diseases is possible to reach a successful outcome if a therapy is available.
T546 13932-14124 Sentence denotes In order to decide who to treat, and when to start treatment, it is important to define the entity of dysfunctions, probability of treatment success and probability to develop adverse effects.
T547 14125-14238 Sentence denotes To promptly intervene in order to prevent severe forms of COVID-19, we need early markers of disease progression.
T548 14239-14635 Sentence denotes To this regard, if plasma (free) Zn2+ (or total zinc/albumin molar ratio), albumin, IL-10, Ang (1–9), Ang (1–7), Ang (1–5) and/or bradykinin (1–7) will be proven to be reliable surrogate markers for ACE and/or ACE2 enzymatic activity in vivo, they could be exploited, together with circulating ACE and ACE2 activity evaluation, in order to decide who and when to start treating COVID-19 patients.
T549 14636-14734 Sentence denotes Alternatively, eosinopaenia and hypotension may be also exploited as signs of disease progression.
T550 14735-15161 Sentence denotes In any case, since the conditions of some patients can be critical, it is highly recommended to administer the minimal effective dose in order to reduce possible side effects, starting with low and increasing doses, while at the same time monitoring patient status and early signs of disease progression (e.g., blood pressure, eosinophil counts, molecular concentrations of the RAS peptides and other markers of inflammation).
T551 15162-15562 Sentence denotes The aim of the project was not necessarily to stop viral entry (the epithelial cells take already care of it shedding ACE2) but to block positive feedback loops that follow the cellular response to SARS-CoV-2 infection, which are likely the main cause of the severe symptoms associated with COVID-19, doing so, the disease might hopefully become like a simple flu, a spontaneously eradicable disease.
T552 15563-15693 Sentence denotes At the moment, I am alone in proposing these new and non-conventional therapeutic approaches that may or may not work on COVID-19.
T553 15694-15879 Sentence denotes In doing so, I have not only described a rationale/strategy to counter COVID-19, but also provided practical information to optimize the RAS inhibitors based on known experimental data.
T554 15880-16069 Sentence denotes Before any in vivo drug administration (e.g., ACE2 inhibitor), it has to be checked the biological activity (e.g., ACE2) that is affected by the drug, considering the possible side effects.
T555 16070-16248 Sentence denotes However, this is not always the case and, in some cases, patients are treated without a careful evaluation of the biological parameter that is modulated by the administered drug.
T556 16249-16461 Sentence denotes In this regard, I have tried to address all aspects of the RAS inhibition in detail because my main concern is that the use of these approaches in a wrong way may lead to a failure or even to deleterious effects.
T557 16462-16705 Sentence denotes That is why I have meticulously described all the steps before possible administration and provided the guideline suggestions and specific recommendations in order to increase the probability of success and to minimize the deleterious effects.
T558 16706-16806 Sentence denotes The readers are, however, expected and encouraged to debate and make their own optimized guidelines.

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T159 596-603 Phenotype denotes hypoxia http://purl.obolibrary.org/obo/HP_0012418
T160 1110-1117 Phenotype denotes colitis http://purl.obolibrary.org/obo/HP_0002583
T161 2535-2546 Phenotype denotes hypercapnia http://purl.obolibrary.org/obo/HP_0012416
T162 4278-4304 Phenotype denotes Inflammatory bowel disease http://purl.obolibrary.org/obo/HP_0002037
T163 4306-4315 Phenotype denotes gastritis http://purl.obolibrary.org/obo/HP_0005263
T164 4320-4327 Phenotype denotes colitis http://purl.obolibrary.org/obo/HP_0002583
T165 7791-7803 Phenotype denotes hypertension http://purl.obolibrary.org/obo/HP_0000822
T166 8001-8008 Phenotype denotes hypoxia http://purl.obolibrary.org/obo/HP_0012418
T167 8172-8185 Phenotype denotes hyperactivity http://purl.obolibrary.org/obo/HP_0000752
T168 8902-8915 Phenotype denotes hyperactivity http://purl.obolibrary.org/obo/HP_0000752
T169 9214-9221 Phenotype denotes hypoxia http://purl.obolibrary.org/obo/HP_0012418
T170 9722-9729 Phenotype denotes hypoxia http://purl.obolibrary.org/obo/HP_0012418
T171 9734-9749 Phenotype denotes cardiac failure http://purl.obolibrary.org/obo/HP_0001635
T172 9804-9818 Phenotype denotes cytokine storm http://purl.obolibrary.org/obo/HP_0033041
T173 14668-14679 Phenotype denotes hypotension http://purl.obolibrary.org/obo/HP_0002615

2_test

Id Subject Object Predicate Lexical cue
32708755-12358520-20679021 2392-2395 12358520 denotes 113
32708755-22777933-20679022 2518-2521 22777933 denotes 115
32708755-15791205-20679023 2728-2730 15791205 denotes 24
32708755-20797602-20679024 3131-3133 20797602 denotes 52
32708755-18235039-20679025 3134-3137 18235039 denotes 117
32708755-20300067-20679026 3138-3141 20300067 denotes 118
32708755-19517214-20679027 3142-3145 19517214 denotes 122
32708755-23370913-20679028 3146-3149 23370913 denotes 183
32708755-31982938-20679029 3150-3153 31982938 denotes 184
32708755-20797602-20679030 3688-3690 20797602 denotes 52
32708755-23370913-20679031 3691-3694 23370913 denotes 183
32708755-31982938-20679032 3695-3698 31982938 denotes 184
32708755-19517214-20679033 4027-4030 19517214 denotes 122
32708755-19517214-20679034 4112-4115 19517214 denotes 122
32708755-31645418-20679035 5229-5232 31645418 denotes 185
32708755-18223027-20679036 7199-7202 18223027 denotes 116
32708755-27432541-20679037 9925-9928 27432541 denotes 182
32708755-20717537-20679038 10266-10269 20717537 denotes 123
32708755-20717537-20679039 10314-10317 20717537 denotes 123
32708755-20717537-20679040 10941-10944 20717537 denotes 123
32708755-14007184-20679041 11321-11324 14007184 denotes 188
32708755-14007184-20679042 11594-11597 14007184 denotes 188
32708755-14007184-20679043 11739-11742 14007184 denotes 188
32708755-20717537-20679044 12375-12378 20717537 denotes 123
32708755-11149993-20679045 12480-12483 11149993 denotes 191
32708755-20717537-20679046 12956-12959 20717537 denotes 123